CYFIP related Rac1 interactor AGenealiases: CYRI-A · FAM49A
Q-omics provides the consensus-scored CYRIA profile across patient tissues and cancer cell-line models. CYRIA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CYRIA is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CYRIA protein abundance shows 26,574 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where CYRIA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYRIA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYRIA survival associations across molecular data types. CYRIA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYRIA RNA expression–survival associations across cancer types. High CYRIA expression shows unfavorable associations in KIRP, UVM, BLCA and UCEC, but favorable associations in LUAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CYRIA RNA expression.
This table summarizes CYRIA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYRIA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYRIA shows lower tumor expression in COAD, UCEC, LUAD and THCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher CYRIA RNA expression in tumor versus normal tissue (log2 FC = +1.539, t-test p < 0.001).
This table shows molecular features associated with CYRIA in patient tissues and cancer cell lines. In patient samples, CYRIA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYRIA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
